San Francisco Bay Area Adult Glioma Prognosis Study Protocol
- Determine factors related to glioma survival in patients from two population-based case
series collected in the San Francisco Bay Area between August 1991 and April 1994
(series 1) and May 1997 and August 1999 (series 2).
- Determine vital status for 879 patients in the two San Francisco Bay Area
population-based series through July 2004.
- Determine survival as a function of established, potential, and yet unstudied
- Gather data to validate results from this study with information from adult glioma
patients enrolled prospectively at the UCSF-Neuro-Oncology clinic and through series 3
of the San Francisco Bay Area Adult Glioma Study; incorporate results from this study
and other components of the SPORE into ongoing clinical investigations at the Brain
Tumor Research Center and Neuro-Oncology Service at UCSF.
- Using funding from the organization Accelerate Brain Cancer Cure (ABC2), genotype
several thousand single nucleotide polymorphisms (SNPs) from some study participants;
assess these SNPs for potential relationship to glioma survival.
OUTLINE: Medical records of patients registered to the California Cancer Registry or the
Northern California Cancer Center SEER are reviewed for mortality and treatment information
related to the brain tumor. Blood and buccal specimens are collected from patients with
newly diagnosed disease who are being seen at the UCSF Neuro-Oncology Service. The specimens
are used for polymporphism and tumor marker studies and other pertinent data. Tumor
specimens and treatment information related to the brain tumor are also collected from the
SPORE Tissue Core.
Additional tumor makers are studied, including: chromosome 1p/19q, 7q studies; DNA repair
and oxidative metabolism polymorphisms; and up to 2 tumor markers and 2 constitutive
Factors related to glioma survival
University of California, San Francisco
|UCSF Helen Diller Family Comprehensive Cancer Center||San Francisco, California 94115|